Orchid Pharma shares experienced strong investor confidence following the announcement of its exclusive licensing and supply agreement with Pharmasyntez JSC for Exblifep commercialization in Russia. The stock surged 8.51% to ₹1,005.50 on Wednesday, July 8, demonstrating robust market response to the strategic partnership. As per Business Standard, the triple-digit PE pharma stock has shown remarkable momentum with a 20% gain in the last one month itself, taking its year-to-date advance to 27%. The Chennai-based company continues to trade above the ₹1,000-mark with the surge in intraday share price, defying broader market trends and highlighting investor confidence in the company's international expansion strategy.
Orchid Pharma and Pharmasyntez JSC have officially entered into an exclusive licensing and supply agreement for Exblifep (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram negative bacterial pathogens. According to corporate notifications filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the agreement establishes a strict operational division of labor where Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, while Orchid will supply the finished dosage form. The deal provides Orchid Pharma access to the Russian market through an exclusive commercialization partner while allowing the company to generate revenue by supplying the finished dosage form, marking the commercialization of Exblifep in the Russian market subject to regulatory approval by the Ministry of Health of the Russian Federation.
The partnership's strategic significance was emphasized by executive leaders from both organizations. Manish Dhanuka, Managing Director of Orchid Pharma Ltd., stated that "Our partnership with Pharmasyntez marks an important step in making Exblifep available to patients in Russia. Pharmasyntez's deep reach into the Russian hospital procurement system makes them the right partner to ensure this medicine gets to the clinicians and patients who need it." From the Russian distributor side, Natalia Malykh, Vice President of Business Development at Pharmasyntez group, highlighted the medical importance, stating that "Antimicrobial resistance is one of the most significant challenges facing modern medicine, making the development of new antibiotics critical. Orchid Pharma has met this challenge by developing the novel antibiotic Exblifep (cefepime/enmetazobactam). This licensing agreement with Pharmasyntez enables Russian patients to gain access to modern antibacterial therapy." The partnership also highlights Orchid Pharma's transition from being primarily an antibiotic manufacturer to a company focused on innovation and drug discovery.
Exblifep is a carbapenem-sparing antibiotic designed to treat serious hospital-acquired infections, including complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP). As reported by Business Standard, the product is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals. The product is specifically developed to address the growing clinical challenge posed by extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria in serious hospital infections. The operational rollout remains contingent upon formal regulatory clearance from the Ministry of Health of the Russian Federation.
The partnership represents a potential opportunity of approximately $178 million over the first 10 years, reflecting the scale of unmet clinical need and significant hospital procurement volumes in the Russian market. Under the agreement, Pharmasyntez will receive exclusive rights to register and commercialise Exblifep in Russia, subject to approval from the Russian health ministry, while Orchid Pharma will continue to manufacture and supply the finished pharmaceutical product. If regulatory approval is secured in Russia and adoption increases through hospital procurement, the partnership could contribute to Orchid Pharma's next phase of international expansion and revenue growth, creating a long-term revenue stream beyond Orchid Pharma's existing operations. The Chennai-based company operates as a fully vertically integrated pharmaceutical company with end-to-end capabilities across Key Starting Materials (KSMs), Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms (FDFs), specializing in the development and manufacturing of complex injectable antibiotics.
Orchid Pharma's latest financial performance shows continued growth momentum with the company reporting a 6.68% increase in consolidated net profit to ₹23.78 crore for Q4 FY26, compared with ₹22.29 crore in the corresponding quarter last year. According to Business Standard, revenue from operations rose marginally to ₹237.61 crore in Q4 FY26 as against ₹237.48 crore posted in the same period last year. The global antibiotics market was valued at approximately $45 billion in 2025 and is projected to grow at a 2.5% CAGR through 2035, reaching around $57 billion by 2034. In 2026, Cephalosporins (32%) and Penicillins (28%) represent the largest shares of the global antibiotic drug market, followed by Others (18%), Macrolides (8%), Carbapenems (8%), and Fluoroquinolones (6%), with the Cephalosporin market valued at around $15 billion in 2025.
